// App-Quantinova.ai

: Phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma

Researchers

Presenter

  • Salman Siddiqui

Principal Investigators

  • Michael Bozik

  • Donald Archibald

  • Steven Dworetzky

  • James Mather

  • Randall Killingsworth

  • Sergei Ochkur

  • Elizabeth Jacobsen

  • Reynold Panettieri

  • Calman Prussin

Medical Centers

  • Rutgers Institute for Translational Medicine and Science, New Brunswick, United States of America

  • Knopp Biosciences LLC, Pittsburgh, United States of America

  • Mayo Clinic, Scottsdale, United States of America

  • NIHR Leicester Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • dexpramipexole

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT04046939

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved